181 related articles for article (PubMed ID: 7379049)
1. Phase II study of VM-26 in adult malignancies.
Spremulli E; Schulz JJ; Speckhart VJ; Wampler GL
Cancer Treat Rep; 1980 Jan; 64(1):147-9. PubMed ID: 7379049
[No Abstract] [Full Text] [Related]
2. Phase II study of teniposide in advanced breast cancer.
Boas J; Rasmussen D; Hansen OP; Engelholm SA; Dombernowsky P
Cancer Chemother Pharmacol; 1990; 25(6):463-4. PubMed ID: 2311176
[TBL] [Abstract][Full Text] [Related]
3. Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study.
Qazi R; Elson P; Khandekar JD
Cancer Treat Rep; 1982 Feb; 66(2):405-6. PubMed ID: 7055823
[No Abstract] [Full Text] [Related]
4. High-dose teniposide for refractory malignancies: a phase I study.
de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of teniposide in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial.
Locker GY; Lanzotti V; Khandekar JD; Sweet D; Shaw J; Bitran J; Gordon L; Krauss S; Johnson C
Cancer Treat Rep; 1986 Feb; 70(2):307-8. PubMed ID: 3948195
[No Abstract] [Full Text] [Related]
6. Phase II trial of VM-26 in patients with metastatic malignant melanoma.
Bellet RE; Catalno RB; Mastrangelo MJ; Berd D; Koons LS
Cancer Treat Rep; 1978 Mar; 62(3):445-7. PubMed ID: 348313
[No Abstract] [Full Text] [Related]
7. Teniposide in refractory ovarian cancer: a phase II study.
Sessa C; D'Incalci M; Landoni F; Colombo N; Mangioni C
Cancer Treat Rep; 1984 May; 68(5):815-6. PubMed ID: 6722838
[No Abstract] [Full Text] [Related]
8. Combination VM-26 and adriamycin for metastatic transitional cell carcinoma.
Rodriguez LH; Johnson DE; Holoye PY; Samuels ML
Cancer Treat Rep; 1977; 61(1):87-8. PubMed ID: 324624
[No Abstract] [Full Text] [Related]
9. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Radice PA; Bunn PA; Ihde DC
Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
[No Abstract] [Full Text] [Related]
10. VM-26 as a second drug in the treatment of brain gliomas.
Kessinger A; Lemon HM; Foley JF
Cancer Treat Rep; 1979 Mar; 63(3):511-2. PubMed ID: 427830
[TBL] [Abstract][Full Text] [Related]
11. [Phase I trial and pharmacokinetics of VM 26 combined with cisplatin administered by the intraperitoneal route without mixing time].
Chatelut E; Canal P; De Forni M; Chevreau C; Houin G; Bugat R
Bull Cancer; 1989; 76(8):893-6. PubMed ID: 2620120
[No Abstract] [Full Text] [Related]
12. [Value of chemotherapy associated with conventional treatment of malignant gliomas of the brain. Study of 95 cases with histological verification and follow-up of 1 to 6 years 9 months].
Paillas JE; Prince MA; Hassoun J; Pellet W; Peragut JC
Rev Neurol (Paris); 1979 Mar; 135(3):251-62. PubMed ID: 227020
[No Abstract] [Full Text] [Related]
13. Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.
Vaughn CB; Panettiere F; Thigpen T; Bottomley R; Hoogstraten B; Samal B
Cancer Treat Rep; 1981; 65(5-6):443-5. PubMed ID: 7237465
[No Abstract] [Full Text] [Related]
14. Teniposide: a review of 12 years of experience.
O'Dwyer PJ; Alonso MT; Leyland-Jones B; Marsoni S
Cancer Treat Rep; 1984 Dec; 68(12):1455-66. PubMed ID: 6391663
[No Abstract] [Full Text] [Related]
15. Teniposide in epithelial ovarian carcinoma: a phase II trial of the Gynecologic Oncology Group.
Muss H; Bundy BN; DiSaia PJ; Twiggs LB
Cancer Treat Rep; 1986 Oct; 70(10):1231-2. PubMed ID: 3530450
[No Abstract] [Full Text] [Related]
16. Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group.
Bleyer WA; Krivit W; Chard RL; Hammond D
Cancer Treat Rep; 1979 Jun; 63(6):977-81. PubMed ID: 380803
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial.
Cox EB; Vogel CL; Carpenter JT; Raney M
Invest New Drugs; 1988 Apr; 6(1):37-9. PubMed ID: 3410666
[TBL] [Abstract][Full Text] [Related]
18. Use of VM-26 as a single agent in the treatment of renal carcinoma.
Hire EA; Samson MK; Fraile RJ; Baker LH
Cancer Clin Trials; 1979; 2(4):293-5. PubMed ID: 394865
[TBL] [Abstract][Full Text] [Related]
19. [The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)].
Jankowski RP; Vahrson H
Med Klin; 1977 Dec; 72(49):2122-6. PubMed ID: 337083
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of teniposide (VM-26) in multiple myeloma.
Tirelli U; Carbone A; Zagonei V; Brema F; Veronesi A; Grigoletto E; Volpe R
Am J Clin Oncol; 1985 Aug; 8(4):329-31. PubMed ID: 3909805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
